RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function.
RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath (NBDS) cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.
The company has received Health Canada Clearance and UBC Ethics approval to conduct its Phase 1/2 clinical trial for the treatment of chronic Achilles tendinosis.
The RCT-01 chronic Achilles tendinosis clinical research study will take place at the University of British Columbia in Vancouver, BC.